IL-13

Representative image: A dermatologist examines an eczema flare, reflecting how EBGLYSS and other atopic dermatitis biologics are shifting the treatment conversation toward fewer injections, longer disease control, and lower patient burden.

Features & Analysis

How EBGLYSS shows the eczema market is moving from breakthrough launches to lifecycle strategy

by Pallavi Madhiraju
June 11, 2026
0 Comments

Find out why fewer injections and longer disease control are becoming key battlegrounds in eczema biologics and dermatology care.

Read More

Representative image of an atopic dermatitis drug development concept, illustrating how Zai Lab’s ZL-1503 is being positioned to target itch and inflammation pathways in early-stage immunology research.

Pharma & Biotech

Can Zai Lab’s ZL-1503 turn dual-pathway itch control into a real atopic dermatitis advantage?

by Pallavi Madhiraju
April 18, 2026
0 Comments

Zai Lab’s ZL-1503 showed durable preclinical itch and inflammation control. Read what its 2026 clinical path could mean for atopic dermatitis.

Read More